CD137+ T cells were considered tumor-specific, and recently, we demonstrated that this cellular subset evaluated before therapy was an independent prognostic factor in advanced NSCLC patients who underwent immunotherapy as the first line (16). Here, TNFRSF9 is linked to neoplasm.